Figure 4. CAR through week 52 (weeks 9–52 for varenicline and weeks 8–52 for NRT) for the Primary Analysis Population (all randomised and treated participants who took at least one dose of study medication). Results of the All Randomised Population CAR for the same period: varenicline, 25.9%; NRT, 19.8% (OR 1.44, 95% CI 1.02 to 2.03; p = 0.040). CAR, continuous abstinence rate; NRT, nicotine replacement therapy; OR, odds ratio; CI, confidence intervals.
